2127 Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer

Rui‐Hua Xu(Sun Yat-sen University), Ping Wen(South China Normal University), Wan Zhi-qiang, Yue Yin Xia, L. Yuhong, L. Daren, Wenhui Wei(University of Michigan), Mei Dong, Dongsheng Zhao, Hai-xia Hua, L. Yin Chen

European Journal of Cancer

September 1, 2015

10.1016/s0959-8049(16)31049-8

Cited by 0

Related Papers

Circular RNA: metabolism, functions and interactions with proteins

|Molecular Cancer|2020|1.6k

METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma

|Molecular Cancer|2019|868

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

|The Lancet|2023|701

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

|Cancer Communications|2021|657

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

|Annals of Oncology|2017|591